Latest Period
Q4 2025
Security Snapshot
Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX) Institutional Ownership
CUSIP: G7709Q104
13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026
Institutions Reporting
534
Shares (Excl. Options)
356,857,360
Price
$38.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Class A Ordinary Shares, par value $0.0001 per share
- Symbol
- RPRX on Nasdaq
- Shares outstanding
- 424,966,351
- Price per share
- $47.97
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 356,857,360
- Total reported value
- $13,780,231,188
- % of total 13F portfolios
- 0.01%
- Share change
- +26,306,481
- Value change
- +$1,029,437,168
- Number of holders
- 534
- Price from insider filings
- $47.97
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- RPRX - Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share is tracked under CUSIP G7709Q104.
- 534 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 534 to 131 between Q4 2025 and Q1 2026.
- Reported value moved from $13,780,231,188 to $422,396,260.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 534 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP G7709Q104?
CUSIP G7709Q104 identifies RPRX - Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G7709Q104:
Significant Owners of Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Legorreta Pablo G. | 20% | $3,372,819,557 | 103,112,796 | Legorreta G. Pablo | 16 May 2025 | |||
| MORGAN STANLEY | 9.2% | $1,394,427,274 | 38,907,011 | Morgan Stanley | 30 Jun 2025 | |||
| Capital International Investors | 7.7% | +16% | $1,265,287,125 | +$163,578,499 | 32,745,526 | +15% | Capital International Investors | 31 Dec 2025 |
| FMR LLC | 6.5% | -29% | $984,337,180 | -$400,247,331 | 27,900,714 | -29% | FMR LLC | 30 Sep 2025 |
| BlackRock, Inc. | 5.7% | $832,319,492 | 25,445,414 | BlackRock, Inc. | 31 Dec 2024 | |||
| Severgnini Achille G. | 5.7% | -17% | $978,612,513 | -$230,404,755 | 24,223,082 | -19% | Severgnini Achille G. | 06 Nov 2025 |
| GENERAL ATLANTIC, L.P. | 3.2% | $510,500,301 | 14,243,870 | General Atlantic, L.P. | 30 Jun 2025 | |||
| VANGUARD GROUP INC | 2.5% | $385,841,061 | 10,936,538 | The Vanguard Group | 30 Sep 2025 |
As of 31 Dec 2025, 534 institutional investors reported holding 356,857,360 shares of Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX). This represents 84% of the company’s total 424,966,351 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX) together control 62% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 13% | 55,274,069 | +25% | 0.13% | $2,135,790,095 |
| Capital International Investors | 7.3% | 31,104,309 | +14% | 0.19% | $1,201,870,500 |
| FMR LLC | 6.2% | 26,272,308 | -6.1% | 0.05% | $1,015,161,996 |
| BlackRock, Inc. | 6.2% | 26,188,692 | -0.05% | 0.02% | $1,011,931,068 |
| BAILLIE GIFFORD & CO | 4% | 17,008,768 | -2.1% | 0.55% | $657,218,795 |
| Swedbank AB | 2.8% | 11,942,143 | -2.1% | 0.45% | $461,444,406 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.8% | 11,740,594 | -1.9% | 0.69% | $453,656,552 |
| STATE STREET CORP | 2.5% | 10,649,641 | +3.7% | 0.01% | $411,502,128 |
| VANGUARD GROUP INC | 2.3% | 9,934,612 | -9.2% | 0.01% | $383,873,407 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 7,719,843 | +1.3% | 0.02% | $297,465,419 |
| Caledonia (Private) Investments Pty Ltd | 1.7% | 7,377,038 | -2.3% | 5.5% | $285,048,748 |
| CITADEL ADVISORS LLC | 1.2% | 5,273,865 | +1236% | 0.14% | $203,782,144 |
| VICTORY CAPITAL MANAGEMENT INC | 1.2% | 5,106,905 | +9.7% | 0.11% | $197,330,809 |
| JANE STREET GROUP, LLC | 1.2% | 4,947,409 | +57% | 0.23% | $191,167,884 |
| NORTHERN TRUST CORP | 0.94% | 4,003,322 | -1.8% | 0.02% | $154,688,363 |
| NORGES BANK | 0.8% | 3,414,165 | 0.01% | $131,923,336 | |
| Patient Capital Management, LLC | 0.78% | 3,333,675 | +6.9% | 5% | $128,813,194 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.78% | 3,313,265 | +0.95% | 0.07% | $128,024,560 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.73% | 3,118,865 | -0.35% | 0.03% | $120,512,944 |
| Legal & General Group Plc | 0.73% | 3,088,098 | +9.4% | 0.03% | $119,324,106 |
| NEW SOUTH CAPITAL MANAGEMENT INC | 0.69% | 2,928,778 | +0.36% | 5.2% | $113,167,982 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.69% | 2,913,398 | -3.7% | 0.02% | $112,573,699 |
| BANK OF AMERICA CORP /DE/ | 0.64% | 2,708,925 | +2.3% | 0.01% | $104,672,844 |
| Amundi | 0.63% | 2,679,379 | +29% | 0.03% | $103,531,205 |
| Regal Partners Ltd | 0.62% | 2,640,708 | +84% | 5.9% | $102,036,956 |
Institutional Holders of Royalty Pharma plc - Class A Ordinary Shares, par value $0.0001 per share (RPRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 8,813,729 | $422,396,260 | +$8,526,187 | $47.97 | 131 |
| 2025 Q4 | 356,857,360 | $13,780,231,188 | +$1,029,437,168 | $38.64 | 534 |
| 2025 Q3 | 327,857,254 | $11,565,432,295 | -$513,196,140 | $35.28 | 484 |
| 2025 Q2 | 342,210,637 | $12,333,363,729 | +$949,776,240 | $36.03 | 452 |
| 2025 Q1 | 317,255,108 | $9,879,343,045 | -$34,196,805 | $31.13 | 444 |
| 2024 Q4 | 320,707,173 | $8,183,523,072 | +$144,649,409 | $25.51 | 414 |
| 2024 Q3 | 312,434,792 | $8,832,030,084 | -$70,655,781 | $28.29 | 391 |
| 2024 Q2 | 316,171,106 | $8,334,967,211 | +$126,311,822 | $26.37 | 373 |
| 2024 Q1 | 311,994,207 | $9,469,625,864 | +$68,283,642 | $30.37 | 375 |
| 2023 Q4 | 310,848,061 | $8,731,929,890 | +$90,598,401 | $28.09 | 359 |
| 2023 Q3 | 300,556,312 | $8,159,558,450 | -$95,718,367 | $27.14 | 312 |
| 2023 Q2 | 302,776,880 | $9,312,865,143 | +$35,406,560 | $30.74 | 321 |
| 2023 Q1 | 301,740,017 | $10,870,806,631 | +$87,185,612 | $36.03 | 331 |
| 2022 Q4 | 299,214,570 | $11,818,548,636 | +$83,591,490 | $39.52 | 332 |
| 2022 Q3 | 298,186,963 | $11,983,269,244 | +$263,400,168 | $40.18 | 311 |
| 2022 Q2 | 291,545,338 | $12,256,604,812 | +$918,924,477 | $42.04 | 281 |
| 2022 Q1 | 270,383,631 | $10,536,275,796 | +$82,755,109 | $38.96 | 272 |
| 2021 Q4 | 268,200,640 | $10,687,984,091 | +$139,946,049 | $39.85 | 254 |
| 2021 Q3 | 265,367,304 | $9,590,727,932 | +$538,289,516 | $36.14 | 226 |
| 2021 Q2 | 250,410,928 | $10,263,954,175 | +$118,347,007 | $40.99 | 229 |
| 2021 Q1 | 246,400,511 | $10,747,503,399 | +$874,104,377 | $43.62 | 208 |
| 2020 Q4 | 226,132,987 | $11,317,812,164 | +$1,961,711,795 | $50.05 | 188 |
| 2020 Q3 | 155,310,287 | $6,522,638,173 | +$367,540,942 | $42.07 | 129 |
| 2020 Q2 | 146,093,806 | $7,034,558,503 | +$7,034,558,867 | $48.55 | 119 |
| 2020 Q1 | 15 | $1,000 | $66.67 | 1 | |
| 2019 Q4 | 15 | $1,000 | $66.67 | 1 | |
| 2019 Q3 | 15 | $1,000 | $66.67 | 1 | |
| 2019 Q2 | 15 | $1,000 | $66.67 | 1 | |
| 2019 Q1 | 15 | $1,000 | $66.67 | 1 |